Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1215

1.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30238-8. doi: 10.1016/S1474-4422(19)30238-8. [Epub ahead of print]

PMID:
31492652
2.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30239-X. doi: 10.1016/S1474-4422(19)30239-X. [Epub ahead of print]

PMID:
31492651
3.

Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis.

Acquaviva M, Bassani C, Sarno N, Dalla Costa G, Romeo M, Sangalli F, Colombo B, Moiola L, Martinelli V, Comi G, Farina C.

Front Immunol. 2019 Aug 14;10:1922. doi: 10.3389/fimmu.2019.01922. eCollection 2019.

4.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5). pii: e591. doi: 10.1212/NXI.0000000000000591. Print 2019 Sep.

5.

Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.

Preziosa P, Rocca MA, Riccitelli GC, Moiola L, Storelli L, Rodegher M, Comi G, Signori A, Falini A, Filippi M.

Neurotherapeutics. 2019 Aug 26. doi: 10.1007/s13311-019-00781-w. [Epub ahead of print]

PMID:
31452082
6.

Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis.

Rintala A, Matcham F, Radaelli M, Locafaro G, Simblett S, Barattieri di San Pietro C, Bulgari V, Burke P, Devonshire J, Weyer J, Wykes T, Comi G, Hotopf M, Myin-Germeys I; on the behalf of the RADAR-CNS Consortium.

J Psychosom Res. 2019 Sep;124:109761. doi: 10.1016/j.jpsychores.2019.109761. Epub 2019 Jul 5. Review.

PMID:
31443806
7.

Limitations in daily activities and general perception of quality of life: Long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy.

Campagnolo M, Ruiz M, Falzone YM, Ermani M, Bianco M, Martinelli D, Cerri F, Quattrini A, Salvalaggio A, Castellani F, Comi G, Giannini F, Nobile-Orazio E, Fazio R, Riva N, Briani C.

J Peripher Nerv Syst. 2019 Sep;24(3):276-282. doi: 10.1111/jns.12342. Epub 2019 Aug 26.

PMID:
31397934
8.

Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.

Pisa M, Ratti F, Vabanesi M, Radaelli M, Guerrieri S, Moiola L, Martinelli V, Comi G, Leocani L.

Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603. [Epub ahead of print]

PMID:
31392924
9.

Activity evaluation of pure and doped zinc oxide nanoparticles against bacterial pathogens and Saccharomyces cerevisiae.

Zanet V, Vidic J, Auger S, Vizzini P, Lippe G, Iacumin L, Comi G, Manzano M.

J Appl Microbiol. 2019 Aug 6. doi: 10.1111/jam.14407. [Epub ahead of print]

PMID:
31386785
10.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5):e591. doi: 10.1212/NXI.0000000000000591. eCollection 2019 Sep.

11.

The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "in Vivo" in the Differential Diagnosis of Alzheimer's Dementia.

Santangelo R, Dell Edera A, Sala A, Cecchetti G, Masserini F, Caso F, Pinto P, Leocani L, Falautano M, Passerini G, Martinelli V, Comi G, Perani D, Magnani G.

Curr Alzheimer Res. 2019 Jul 25. doi: 10.2174/1567205016666190725150836. [Epub ahead of print]

PMID:
31345148
12.

In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis.

Vabanesi M, Pisa M, Guerrieri S, Moiola L, Radaelli M, Medaglini S, Martinelli V, Comi G, Leocani L.

Sci Rep. 2019 Jul 17;9(1):10371. doi: 10.1038/s41598-019-46251-3.

13.

Non-invasive visual evoked potentials to assess optic nerve involvement in the dark agouti rat model of experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein.

Castoldi V, Marenna S, d'Isa R, Huang SC, De Battista D, Chirizzi C, Chaabane L, Kumar D, Boschert U, Comi G, Leocani L.

Brain Pathol. 2019 Jul 3. doi: 10.1111/bpa.12762. [Epub ahead of print]

PMID:
31267597
14.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis.

Peroni S, Sorosina M, Malhotra S, Clarelli F, Osiceanu AM, Ferrè L, Roostaei T, Rio J, Midaglia L, Villar LM, Álvarez-Cermeño JC, Guaschino C, Radaelli M, Citterio L, Lechner-Scott J, Spataro N, Navarro A, Martinelli V, Montalban X, Weiner HL, de Jager P, Comi G, Esposito F, Comabella M, Martinelli-Boneschi F.

Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428. [Epub ahead of print]

PMID:
31221001
15.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24.

16.

Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".

Dalla Costa G, Martinelli V, Furlan R, Comi G.

Ann Neurol. 2019 Aug;86(2):324. doi: 10.1002/ana.25526. Epub 2019 Jun 26. No abstract available.

PMID:
31187511
17.

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.

Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS.

Mult Scler. 2019 Jun 7:1352458519851981. doi: 10.1177/1352458519851981. [Epub ahead of print]

PMID:
31172849
18.

Expanding the spectrum of genes responsible for hereditary motor neuropathies.

Previtali SC, Zhao E, Lazarevic D, Pipitone GB, Fabrizi GM, Manganelli F, Mazzeo A, Pareyson D, Schenone A, Taroni F, Vita G, Bellone E, Ferrarini M, Garibaldi M, Magri S, Padua L, Pennisi E, Pisciotta C, Riva N, Scaioli V, Scarlato M, Tozza S, Geroldi A, Jordanova A, Ferrari M, Molineris I, Reilly MM, Comi G, Carrera P, Devoto M, Bolino A.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1171-1179. doi: 10.1136/jnnp-2019-320717. Epub 2019 Jun 5.

PMID:
31167812
19.

Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis.

Dalla Costa G, Romeo M, Esposito F, Sangalli F, Colombo B, Radaelli M, Moiola L, Comi G, Martinelli V.

Mult Scler Relat Disord. 2019 Aug;33:75-77. doi: 10.1016/j.msard.2019.05.010. Epub 2019 May 21.

PMID:
31158806
20.

Prospects for the Use of Whey for Polyhydroxyalkanoate (PHA) Production.

Amaro TMMM, Rosa D, Comi G, Iacumin L.

Front Microbiol. 2019 May 9;10:992. doi: 10.3389/fmicb.2019.00992. eCollection 2019. Review.

Supplemental Content

Loading ...
Support Center